OR WAIT null SECS
May 01, 2020
The new cell-line producing platform enables fully scalable production of high-performance adeno-associated virus vectors.
The goal of the collaboration is to manufacture up to one billion does per year of mRNA-1273, Moderna’s vaccine against the novel coronavirus.
Sartorius adds chromatography systems and resins, tangential flow filtration, and biomolecular characterization technologies.
Manja Boerman tapped as president of Cell & Gene Therapy for Catalent with retirement of Pete Buzy.
April 30, 2020
Private equity firm, Ampersand Capital Partners, has made a majority investment into contract packaging organization (CPO), Tjoapack.
Catalent and Johnson & Johnson announce joint investment and tech transfer to prepare for rapid scale-up and segregated cGMP commercial manufacturing capacity.
The Cambridge Design Partnership and the Stevanato Group have announced a partnership that will see the development of a new pen-injector based on the Axis-D technology and IP licensed from Haselmeier in 2019.
ILC Therapeutics, a biotech company based in the United Kingdom, has discovered two separate novel treatments for patients suffering with COVID-19 prior to needing ventilators.
Solentim and ATUM will bundle together the Leap-In Transposase platform with the VIPS single cell cloning instrument for cell line development.
The new printers contain integrated PTLab software and can print directly onto slides and cassettes, eliminating handwritten mistakes and expensive labels.